Dr. Vishnevetsky serves as SVP of Business Development and Commercial Operations at Fabric Genomics with a focus on corporate partnerships and strategic alliances. Prior to joining Fabric Genomics Michael focused on Pharma engagement and companion diagnostics (CDx) test development, serving subsequently as a Head of Global Business Development at Personal Genome Diagnostics and Invivoscribe. Prior to that, Dr. Vishnevetsky held business development positions at Pacific Biosciences and Thermo Fisher Scientific with focus on utilization of molecular assays and next-generation sequencing (NGS) for diagnostics of rare diseases and clinical oncology. Prior to that, Dr. Vishnevetsky served and as Vice President of Sales and Marketing at WaferGen Biosystems and held sales management, marketing, and corporate strategy positions of increasing responsibility at Life Technologies-Invitrogen. Dr. Vishnevetsky obtained a postdoctoral appointment in biology from the California Institute of Technology and holds a Ph.D. degree in Molecular Biology from Hebrew University of Jerusalem.
Stephen Kingsmore, Rady Children’s Institute for Genomic Medicine
Kate Kernan, UPMC
The rapid development of genomic sequencing technologies has decreased the cost of genetic analysis to the extent that it seems plausible that genome-scale sequencing could have widespread availability in pediatric care. Genomic sequencing provides a powerful diagnostic modality for patients who manifest symptoms of monogenic disease and an opportunity to detect health conditions before their development. However, many technical, clinical, ethical, and societal challenges should be addressed before such technology is widely deployed in pediatric practice.